Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Clinical trial NCT03937830 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03937830
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-10
- Primary completion
- 2026-12-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.